2.3.4.0 In­di­vid­u­al­iza­tion of Treat­ment Tar­gets

Pa­tients and clin­icians should en­gage in a shared de­ci­sion-‍mak­ing pro­cess to de­ter­mine in­di­vid­u­al blood pres­sure tar­gets (17). This ap­proach ac­knowl­edges that the benefits and risks of in­ten­sive blood pres­sure tar­gets are un­cer­tain and may vary across pa­tients and is con­sis­tent with a pa­tient-focused ap­proach to care that val­ues pa­tient pri­or­i­ties and pro­vider judg­ment (35). Sec­ondary anal­y­ses of AC­CORD BP and SPRINT sug­gest that clin­i­cal fac­tors can help de­ter­mine in­di­vid­u­als more like­ly to benefit and less like­ly to be harmed by in­ten­sive blood pres­sure con­trol (36).

Ab­so­lute benefit from blood pres­sure re­duc­tion cor­re­lated with ab­so­lute base­line car­dio­vas­cu­lar risk in SPRINT and in ear­li­er clin­i­cal tri­als con­duct­ed at high­er base­line blood pres­sure lev­els (11,37). Ex­trap­o­la­tion of these stud­ies sug­gests that pa­tients with di­a­betes may also be more like­ly to benefit from in­ten­sive blood pres­sure con­trol when they have high ab­so­lute car­dio­vas­cu­lar risk. There­fore, it may be rea­son­able to tar­get blood pres­sure <130/80 mmHg among pa­tients with di­a­betes and ei­ther clin­i­cally di­ag­nosed car­dio­vas­cu­lar dis­ease (par­tic­u­lar­ly stroke, which was significant­ly re­duced in AC­CORD BP) or 10-year ASCVD risk ≥15%, if it can be at­tained safe­ly. This ap­proach is con­sis­tent with guide­lines from the Amer­i­can Col­lege of Car­di­ol­o­gy/Amer­i­can Heart As­so­ci­a­tion, which ad­vo­cate a blood pres­sure tar­get <130/80 mmHg for all pa­tients, with or with­out di­a­betes (38).

Po­ten­tial ad­verse ef­fects of an­ti­hy­per­ten­sive ther­a­py (e.g., hy­poten­sion, syn­cope, falls, acute kid­ney in­jury, and elec­trolyte ab­nor­malities) should also be taken into ac­count (28,39–41). Pa­tients with older age, chron­ic kid­ney dis­ease, and frailty have been shown to be at high­er risk of ad­verse ef­fects of in­ten­sive blood pres­sure con­trol (41). In ad­di­tion, pa­tients with or­tho­stat­ic hy­poten­sion, sub­stan­tial comor­bid­i­ty, func­tion­al lim­i­ta­tions, or polyphar­ma­cy may be at high risk of ad­verse ef­fects, and some pa­tients may pre­fer high­er blood pres­sure tar­gets to en­hance qual­i­ty of life. Pa­tients with low ab­so­lute car­dio­vas­cu­lar risk (10-year ASCVD risk <15%) or with a his­to­ry of ad­verse ef­fects of in­ten­sive blood pres­sure con­trol or at high risk of such ad­verse ef­fects should have a high­er blood pres­sure tar­get. In such pa­tients, a blood pres­sure tar­get of <140/90 mmHg is rec­om­mend­ed, if it can be safe­ly at­tained.